Hiroshi Tomiyama

1.3k citations

28 papers · 1.1k indexed · h-index 13

Endocrinology, Diabetes and Metabolism top 2%
Molecular Biology
Surgery top 10%
Organic Chemistry top 10%
Epidemiology

Co-authors: Eiji Kurosaki Atsuo Tahara Toshiyuki Takasu Yuka Hayashizaki Rumi Kihara Atsushi Noda Masayuki Shibasaki Masanori Yokono
Topics: Diabetes Treatment and Management (8 papers)Pancreatic function and diabetes (4 papers)Carbohydrate Chemistry and Synthesis (4 papers)
Cited by: Endocrinology, Diabetes and Metabolism Organic Chemistry Surgery
Journals: Angewandte Chemie International Edition The Journal of Chemical Physics Chemical Physics Letters
Partner nations: Japan Netherlands United States

In The Last Decade

Hiroshi Tomiyama

28 papers receiving 1.1k citations

Peers

Countries citing papers authored by Hiroshi Tomiyama

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Tomiyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Tomiyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Tomiyama more than expected).

Fields of papers citing papers by Hiroshi Tomiyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Tomiyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Tomiyama. The network helps show where Hiroshi Tomiyama may publish in the future.

Co-authorship network of co-authors of Hiroshi Tomiyama

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Tomiyama. A scholar is included among the top collaborators of Hiroshi Tomiyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Tomiyama. Hiroshi Tomiyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of ASP5878: Synthesis and structure–activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity 2022 ·Bioorganic & Medicinal Chemistry ·(unknown),Minoru Kameda,(unknown),(unknown),Yuichiro Kawamoto,(unknown),Hiroyuki Moritomo,Tadashi Terasaka,(unknown),Atsushi Noda,Hiroshi Tomiyama,(unknown),Masaaki Hirano	8
2	Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency 2021 ·Bioorganic & Medicinal Chemistry ·(unknown),Minoru Kameda,(unknown),(unknown),Yuichiro Kawamoto,(unknown),Hiroyuki Moritomo,(unknown),Tadashi Terasaka,Y. Amano,(unknown),(unknown),(unknown),Atsushi Noda,Hiroshi Tomiyama,(unknown),Masaaki Hirano	9
3	Renoprotective Effects of a Novel Receptor-Interacting Protein Kinase 2 Inhibitor, AS3334034, in Uninephrectomized Adriamycin-Induced Chronic Kidney Disease Rats 2020 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),Mitsuhiro Kondo,(unknown),Akira Nagashima,Kenichi Tokita,(unknown),Hiroshi Tomiyama,Tomohisa Ishikawa	6
4	Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2 2020 ·Bioorganic & Medicinal Chemistry ·(unknown),Minoru Kameda,(unknown),(unknown),(unknown),Yuichiro Kawamoto,Hiroyuki Moritomo,(unknown),Y. Amano,(unknown),(unknown),(unknown),Atsushi Noda,Hiroshi Tomiyama,Tomoyuki Suzuki,Masaaki Hirano	25
5	Synthesis and structure–activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) inhibitors 2019 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),(unknown),(unknown),(unknown),Ayako Moritomo,(unknown),Hiroshi Tomiyama,Itsuro Shimada	7
6	Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats 2018 ·Biomedicine & Pharmacotherapy ·Atsuo Tahara,(unknown),Toshiyuki Takasu,Hiroshi Tomiyama	10
7	SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats 2014 ·European Journal of Pharmacology ·Masanori Yokono,Toshiyuki Takasu,Yuka Hayashizaki,Keisuke Mitsuoka,Rumi Kihara,Yuko Muramatsu,Sosuke Miyoshi,Atsuo Tahara,Eiji Kurosaki,Qun Li,Hiroshi Tomiyama,Masao Sasamata,Masayuki Shibasaki,Yasuo Uchiyama	171
8	Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543 2013 ·Bioorganic & Medicinal Chemistry ·Kazuhiro Ikegai,Masakazu Imamura,Takayuki Suzuki,Keita Nakanishi,Takeshi Murakami,Eiji Kurosaki,Atsushi Noda,Yoshinori Kobayashi,Masayuki Yokota,(unknown),Kazuhiro Kosakai,(unknown),Makoto Takeuchi,Hiroshi Tomiyama,Mitsuaki Ohta	46
9	Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor 2013 ·Endocrine Research ·Masanori Yokono,Atsuo Tahara,Eiji Kurosaki,Daisuke Yamajuku,Rumi Kihara,Masakazu Imamura,Hiroshi Tomiyama,Yoshinori Kobayashi,Atsushi Noda,Masayuki Shibasaki	4
10	Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice 2013 ·European Journal of Pharmacology ·Atsuo Tahara,Eiji Kurosaki,Masanori Yokono,Daisuke Yamajuku,Rumi Kihara,Yuka Hayashizaki,Toshiyuki Takasu,Masakazu Imamura,Qun Li,Hiroshi Tomiyama,Yoshinori Kobayashi,Atsushi Noda,Masao Sasamata,Masayuki Shibasaki	263
11	Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus 2012 ·Bioorganic & Medicinal Chemistry ·Masakazu Imamura,Keita Nakanishi,Takayuki Suzuki,Kazuhiro Ikegai,Ryota Shiraki,(unknown),Takeshi Murakami,Eiji Kurosaki,Atsushi Noda,Yoshinori Kobayashi,Masayuki Yokota,(unknown),Kazuhiro Kosakai,(unknown),Makoto Takeuchi,Hiroshi Tomiyama,Mitsuaki Ohta	107
12	Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^\|^ndash;Nicotinamide-Induced Mildly Diabetic Mice 2012 ·Journal of Pharmacological Sciences ·Atsuo Tahara,Eiji Kurosaki,Masanori Yokono,Daisuke Yamajuku,Rumi Kihara,Yuka Hayashizaki,Toshiyuki Takasu,Masakazu Imamura,Qun Li,Hiroshi Tomiyama,Yoshinori Kobayashi,Atsushi Noda,Masao Sasamata,Masayuki Shibasaki	36
13	Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo 2011 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Atsuo Tahara,Eiji Kurosaki,Masanori Yokono,Daisuke Yamajuku,Rumi Kihara,Yuka Hayashizaki,Toshiyuki Takasu,Masakazu Imamura,Qun Li,Hiroshi Tomiyama,Yoshinori Kobayashi,Atsushi Noda,Masao Sasamata,Masayuki Shibasaki	96
14	Nitrous oxide can enhance the hypnotic effect, but not the suppression of spinal motor neuron excitability by propofol in humans 2006 ·Journal of Anesthesia ·Manabu Kakinohana,(unknown),Hiroshi Tomiyama,Kazuhiro Sugahara	1
15	Regioselective Alkylation of 2-Alkyl-5,6,7,8-tetrahydro-3H-cycloheptimidazol-4-ones and 2-Alkyl-3H-cycloheptimidazol-4-ones 2006 ·Chemical and Pharmaceutical Bulletin ·(unknown),Masayuki Yokota,Hiroshi Tomiyama,(unknown)	9
16	Effective Preparation of Cycloheptimidazol-4-one Compounds 2006 ·Chemical and Pharmaceutical Bulletin ·(unknown),(unknown),Hiroshi Tomiyama,(unknown)	2
17	Synthesis of Double C-Glycoside Analogue of sTn 2005 ·The Journal of Organic Chemistry ·(unknown),Sultan Nacak Baytaş,Qun Wang,Eva Muñoz,(unknown),Hiroshi Tomiyama,Robert J. Linhardt	17
18	Synthesis of a C‐Glycoside Analogue of sTn: An HIV‐ and Tumor‐Associated Antigen 2003 ·Angewandte Chemie International Edition ·Balagurunathan Kuberan,(unknown),Hiroshi Tomiyama,Robert J. Linhardt	62
19	Catalytic asymmetric intramolecular cyclopropanation of enol silyl ether. Synthesis of the phorbol CD-ring skeleton 1996 ·Tetrahedron Letters ·Ryosuke Tokunoh,Hiroshi Tomiyama,Mikiko Sodeoka,Masakatsu Shibasaki	41
20	‘‘Ordered’’ structure in dilute solutions of biopolymers as studied by small-angle x-ray scattering 1985 ·The Journal of Chemical Physics ·Hideki Matsuoka,Norio Ise,Tsuneo Okubo,Shigeru Kunugi,Hiroshi Tomiyama,(unknown)	40

About Hiroshi Tomiyama

Hiroshi Tomiyama is a scholar working on Endocrinology, Diabetes and Metabolism, Anesthesiology and Pain Medicine and Organic Chemistry, having authored 28 papers that have together received 1.1k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (8 papers), Pancreatic function and diabetes (4 papers) and Carbohydrate Chemistry and Synthesis (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (617 citations), Organic Chemistry (245 citations) and Surgery (354 citations). Hiroshi Tomiyama has collaborated with scholars based in Japan, Netherlands and United States. Frequent co-authors include Eiji Kurosaki, Atsuo Tahara, Toshiyuki Takasu, Yuka Hayashizaki, Rumi Kihara, Atsushi Noda, Masayuki Shibasaki, Masanori Yokono, Qun Li and Masao Sasamata. Their work appears in journals such as Angewandte Chemie International Edition, The Journal of Chemical Physics and Chemical Physics Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact